Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new vaccine called ITI-3000 in patients with a specific type of skin cancer who have finished standard treatments and currently show no signs of active disease. The vaccine aims to help their immune systems recognize and attack any remaining cancer cells.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are on ongoing immunosuppressive therapy, you may not be eligible, except for low-dose topical, nasal, or inhaled steroids.
What safety data exists for ITI-3000 or similar treatments?
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single 4 mg dose of the DNA vaccine ITI-3000
Follow-up
Participants are monitored for safety, tolerability, and immunologic response to the ITI-3000 vaccine
What Are the Treatments Tested in This Trial?
Interventions
- ITI-3000
Find a Clinic Near You
Who Is Running the Clinical Trial?
Immunomic Therapeutics, Inc.
Lead Sponsor